Jean L Grem

Summary

Affiliation: University of Nebraska Medical Center
Country: USA

Publications

  1. pmc Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer
    Gregory D Leonard
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Naval Medical Center, Bethesda, MD 20889 5105, USA
    BMC Cancer 5:116. 2005
  2. ncbi request reprint Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer
    Jean L Grem
    Department of Internal Medicine, Section of Oncology Hematology, and the Eppley Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA
    Semin Oncol 32:120-7. 2005
  3. ncbi request reprint Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors
    Jean L Grem
    Nebraska Medical Center, Omaha, NE 68198 7680, USA
    J Clin Oncol 23:1885-93. 2005
  4. doi request reprint Fatigue and other variables during adjuvant chemotherapy for colon and rectal cancer
    Ann M Berger
    University of Nebraska Medical Center in Omaha, USA
    Oncol Nurs Forum 37:E359-69. 2010
  5. pmc Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine
    Kazumi Uchida
    University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE 68198, USA
    BMC Cancer 8:386. 2008
  6. ncbi request reprint Mature results of adjuvant colon cancer trials from the fluorouracil-only era
    Jean L Grem
    J Natl Cancer Inst 96:727-9. 2004
  7. ncbi request reprint A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowel
    Abdel Salam Attia Ismail
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute Navy, National Naval Medical Center, Bethesda, MD 20889 5105, USA
    Oncol Rep 13:1145-52. 2005
  8. ncbi request reprint A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors
    Maurice A Wright
    Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 11:4144-50. 2005
  9. ncbi request reprint Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function
    Chris H Takimoto
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78245 3217, USA
    Clin Cancer Res 13:4832-9. 2007
  10. doi request reprint Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group
    Ramesh K Ramanathan
    Translational Genomics Research Institute, 13208 E Shea Blvd, Ste 100, Scottsdale, AZ 85259, USA
    J Clin Oncol 26:563-9. 2008

Collaborators

Detail Information

Publications27

  1. pmc Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer
    Gregory D Leonard
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Naval Medical Center, Bethesda, MD 20889 5105, USA
    BMC Cancer 5:116. 2005
    ..Oxaliplatin, an agent used in first-line therapy for metastatic colorectal cancer, causes acute and chronic neurotoxicity. This study was performed to carefully assess the incidence, type and duration of oxaliplatin neurotoxicity...
  2. ncbi request reprint Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer
    Jean L Grem
    Department of Internal Medicine, Section of Oncology Hematology, and the Eppley Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA
    Semin Oncol 32:120-7. 2005
    ....
  3. ncbi request reprint Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors
    Jean L Grem
    Nebraska Medical Center, Omaha, NE 68198 7680, USA
    J Clin Oncol 23:1885-93. 2005
    ..To determine the clinical toxicities of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) given as a 1-hour infusion daily for 5 days every 3 weeks...
  4. doi request reprint Fatigue and other variables during adjuvant chemotherapy for colon and rectal cancer
    Ann M Berger
    University of Nebraska Medical Center in Omaha, USA
    Oncol Nurs Forum 37:E359-69. 2010
    ....
  5. pmc Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine
    Kazumi Uchida
    University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE 68198, USA
    BMC Cancer 8:386. 2008
    ..Over-expression of ERCC1 correlates with insensitivity to oxaliplatin (OX) therapy, while high thymidine phosphorylase (TP) levels predict for increased sensitivity to capecitabine (Xel)...
  6. ncbi request reprint Mature results of adjuvant colon cancer trials from the fluorouracil-only era
    Jean L Grem
    J Natl Cancer Inst 96:727-9. 2004
  7. ncbi request reprint A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowel
    Abdel Salam Attia Ismail
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute Navy, National Naval Medical Center, Bethesda, MD 20889 5105, USA
    Oncol Rep 13:1145-52. 2005
    ..6 and 100.0 min, respectively. A 1-h infusion of 5-FU is well tolerated; individual dose escalation of 5-FU allows each patient to receive the maximum tolerable dose...
  8. ncbi request reprint A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors
    Maurice A Wright
    Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 11:4144-50. 2005
    ..In preclinical studies, sequential exposure to irinotecan (CPT-11) then fluorouracil (5-FU) is superior to concurrent exposure or the reverse sequence; a 24-hour infusion of CPT-11 may be better tolerated than shorter infusions...
  9. ncbi request reprint Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function
    Chris H Takimoto
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78245 3217, USA
    Clin Cancer Res 13:4832-9. 2007
    ..To characterize the pharmacokinetics and pharmacodynamics of oxaliplatin in cancer patients with impaired renal function...
  10. doi request reprint Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group
    Ramesh K Ramanathan
    Translational Genomics Research Institute, 13208 E Shea Blvd, Ste 100, Scottsdale, AZ 85259, USA
    J Clin Oncol 26:563-9. 2008
    ..To develop dosing guidelines and to evaluate the pharmacokinetics of imatinib in patients with liver dysfunction (LD)...
  11. doi request reprint Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group
    Joseph Gibbons
    Case Comprehensive Cancer Center, Ireland Cancer Center at University Hospitals of Case Medical Center and Case Western Reserve University School of Medicine, Cleveland, OH, USA
    J Clin Oncol 26:570-6. 2008
    ....
  12. ncbi request reprint Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group
    Chris H Takimoto
    Medicine Branch at Navy, National Naval Medical Center, National Cancer Institute, Bethesda, MD, USA
    Semin Oncol 30:20-5. 2003
    ..These data suggest that dose reductions of single-agent oxaliplatin are not necessary in patients with CrCLs >20 mL/min...
  13. ncbi request reprint Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
    Chris H Takimoto
    University of Texas Health Science Center at San Antonio, Cancer Therapy and Research Center, 7979 Wurzbach Rd, Room Z415, San Antonio, TX 78229, USA
    J Clin Oncol 21:2664-72. 2003
    ..This study was undertaken to determine the toxicities, pharmacokinetics, and maximum tolerated doses of oxaliplatin in patients with renal impairment and to develop formal guidelines for oxaliplatin dosing in this patient population...
  14. ncbi request reprint A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion
    Jorge Leguizamo
    National Cancer Institute Navy Medical Oncology, Cancer Therapeutics Branch, Center for Cancer Research, National Naval Medical Center, Bethesda, Maryland, USA
    Cancer Chemother Pharmacol 52:333-8. 2003
    ....
  15. ncbi request reprint Hypersensitivity and idiosyncratic reactions to oxaliplatin
    Rebecca R Thomas
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, NCI Navy Medical Oncology, National Naval Medical Center, Bethesda, Maryland 20889 5105, USA
    Cancer 97:2301-7. 2003
    ..Oxaliplatin is a third-generation platinum analog that is used to treat a variety of solid tumors, particularly colorectal carcinoma. Patients may develop hypersensitivity reactions, although this complication occurs infrequently...
  16. ncbi request reprint Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule
    Xiao Du Guo
    National Cancer Institute Navy Medical Oncology, Cancer Therapeutics Branch, Center for Cancer Research, National Naval Medical Center, Bethesda, MD 20889 5105, USA
    Cancer Chemother Pharmacol 52:79-85. 2003
    ..To determine the toxicities and pharmacokinetic effects of eniluracil (EU) given on two weekly dosing schedules with 5-fluorouracil (5-FU) and leucovorin (LV)...
  17. ncbi request reprint A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients
    Jean L Grem
    National Cancer Institute Navy Hematology Oncology, National Naval Medical Center, Bethesda, Maryland 20889, USA
    Clin Cancer Res 8:2149-56. 2002
    ..We assessed the clinical toxicities and pharmacologic effects of PZA given as a 24-h i.v. infusion weekly for 3 of 4 weeks...
  18. ncbi request reprint A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin
    Jean L Grem
    National Cancer Institute Navy Medical Oncology, National Naval Medical Center, Bethesda, MD 20889, USA
    Cancer Chemother Pharmacol 52:487-96. 2003
    ..Since preclinical studies have shown more than additive cytotoxicity and DNA damage with the combination of gemcitabine and 5-fluoro-2'-deoxyuridine (FUDR), we studied this combination in a phase I trial...
  19. ncbi request reprint Biochemical and molecular effects of UCN-01 in combination with 5-fluorodeoxyuridine in A431 human epidermoid cancer cells
    Jean L Grem
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute Navy Medical Oncology, National Naval Medical Center, Bethesda, MD 20889 5105, USA
    Anticancer Drugs 13:259-70. 2002
    ..The clinical evaluation of UCN-01 combined with 5-fluoropyrimidines may be of interest...
  20. ncbi request reprint Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition
    Bruce Keith
    National Cancer Institute Navy Medical Oncology, Cancer Therapeutics Branch, Center for Cancer Research, National Naval Medical Center, Bethesda, Maryland 20889 5105, USA
    Clin Cancer Res 8:1045-50. 2002
    ..This study determined the effect of different weekly dosing schedules of 5-fluorouracil (5-FU)/leucovorin (LV)/eniluracil on dihydropyrimidine dehydrogenase (DPD) activity and plasma uracil levels...
  21. ncbi request reprint Epirubicin, Cisplatin, and protracted venous-infusion Fluorouracil in advanced esophagogastric cancer
    Gregory D Leonard
    J Clin Oncol 20:4124-5; author reply 4125-6. 2002
  22. pmc Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels
    Richard G Webster
    Neurosciences Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Br J Pharmacol 146:1027-39. 2005
    ..The similarity between beta-pompilidotoxin and oxaliplatin suggests that alteration of voltage-gated Na(+) channel kinetics is likely to underlie the acute neurotoxic actions of oxaliplatin...
  23. ncbi request reprint Liquid chromatography-mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma
    Yan Xu
    Gastrointestinal Malignancies Section, Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, 20889 5105, Bethesda, MD, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 783:273-85. 2003
    ..0500-25.0 microgram/ml for the metabolites, 5'-deoxy-5-fluorocytidine and 5'-deoxy-5-fluorouridine, respectively. This method has been used to analyze plasma samples from patients receiving capecitabine in combination with oxaliplatin...
  24. ncbi request reprint Screening for dihydropyrimidine dehydrogenase deficiency
    Jean L Grem
    Clin Cancer Res 11:5067-8. 2005
  25. ncbi request reprint Severe disabling sensory-motor polyneuropathy during oxaliplatin-based chemotherapy
    Gregory D Leonard
    National Cancer Institute Navy Medical Oncology, Bethesda, MD, USA
    Anticancer Drugs 15:733-5. 2004
    ..Heightened clinical suspicion for possible oxaliplatin-induced motor neuropathies may be warranted...
  26. ncbi request reprint Cardiac toxicity associated with capecitabine therapy
    M Wasif Saif
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NCI Navy Medical Oncology, National Naval Medical Center, Bethesda 20889 5105, USA
    Acta Oncol 42:342-4. 2003
  27. ncbi request reprint Acute oxaliplatin-induced peripheral nerve hyperexcitability
    Richard H Wilson
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Clin Oncol 20:1767-74. 2002
    ..Neurotoxicity is dose-limiting and occurs in two distinct forms, an acute neurologic symptom complex that occurs within hours or days of therapy and a chronic, cumulative sensory neuropathy...